Get 25% off STAT+ and access the top stories from April

Get 25% off an annual STAT+ subscription and read more of our award-winning journalism.

My Account    STAT+ Stories Check out last month's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year. DOM SMITH/STAT 1   New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition By Adam Feuerstein NIH/NCI CENTER FOR CANCER RESEARCH 2   Cancer is rising among the young. Study suggests it's because their cells are aging faster By Jonathan Wosen THE BOSTON GLOBE 3   Mass General Brigham is ready to move on without Dana-Farber, CEO says By Bob Herman Subscribe to STAT+ Enjoy discounts on STAT Reports and events, free access to premium data tools, and daily coverage of the life sciences. SUBSCRIBE NOW More Top Stories 4   Generative AI is supposed to save doctors from burnout. New data show it needs more training By Casey Ross 5   Can investing in infectious disease pay off? Vir Biotechnology's tightrope walk shows it's a struggle By Jason Mast 6   The biotech scoreboard for the second quarter: 32 stock-moving events to watch By Adam Feuerstein 7   Taking stock of the frenzied push into autoimmune disease By Adam Feuerstein 8   WHO scientists question Grail's plan for evaluating its multi-cancer Galleri blood test By Matthew Herper 9   Medicare expects to spend $3.5 billion on new Alzheimer's drug in 2025 By Bob Herman and Rachel Cohrs Zhang 10   Biotech startups post strongest financing numbers in two years By Allison DeAngelis read more STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us